Context
BICO Group, previously Cellink, is the world leading bioconvergence company providing innovative and cutting-edge technology, products and services which enables its customers to master biology and create the future of medicine in a rapidly growing field where the total market is expected to be in excess of USD 150bn
BICO has since inception delivered a strong organic growth story based on combining excellent R&D with commercial execution resulting in a game-changing product offering by combining biology and technology
BICO has a proven track-record of executing a value-generating and customer centric M&A agenda enabling strong synergies and time- and cost-efficient workflows to its customers
Capital raise proceeds will be mainly used to further advance the Company’s acquisition agenda and create financial readiness for new opportunities, as well as for the most recent acquisition of QInstruments GmbH on October 1, 2021, at purchase price of EUR 61.25m
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading Bio Convergence company in the world by combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications.
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Joint Bookrunner on BICO’s SEK 2 billion Follow-on Offering
Acting as Joint Bookrunner alongside J.P. Morgan, Carnegie and ABG Sundal Collier, Bryan, Garnier & Co helped to deliver a SEK 2 billion transaction for BICO Group on Nasdaq Stockholm main market
The offering priced at SEK 480 per share, representing a discount of 5.6% on the closing price
Total deal size amounted 4,250,000 shares, equivalent to SEK 2 billion and representing 7.4% of issued share capital
Book of about 150 lines was multiple times oversubscribed
This is another landmark transaction for Bryan, Garnier & Co, which demonstrates its unique ability to raise capital for European healthcare companies in a highly competitive fundraising environment
Share